The Globe and Mail reports in its Monday, Aug. 11, edition that Obesity Canada has updated its treatment guidelines, doubling both the number of drug options and recommendations from its 2020 release. The Globe's Jennifer Yang writes that the new chapter, published in the Canadian Medical Association Journal, highlights the impact of GLP-1 receptor agonists like Ozempic and Novo Nordisk's Wegovy on obesity care. Experts now recommend 13 strategies for prescribing obesity medications alongside health behaviour changes. To gain insight into the evolving landscape of obesity in Canada, Ms. Yang spoke with Sue Pedersen, an endocrinologist and obesity specialist at C-ENDO Clinic in Calgary. A recent paper indicates that obesity among Canadian adults has risen from 25 per cent in 2009 to 33 per cent in 2023. Ms. Pedersen's chapter on pharmacotherapy in Obesity Canada's guidelines has been updated twice in five years due to rapid changes in weight management medications. The updated recommendations now prioritize parameters beyond body mass index (BMI), suggesting metrics like waist-to-height ratio and circumference for prescribing obesity medications.